Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
96-hour patch test and TEWL assessment of antiseptic-induced skin irritation in healthy volunteers
2006-005649-12Phase 4Unknown
- Sponsor
- Regent Medical
- Start
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Hexidine, Tegaderm CHG, povidone-iodine, Sterillium, Stellisept and 1 more in cutaneous reaction (8 arms), sponsored by Regent Medical. Primary endpoints: Skin irritancy potential of antiseptic products and Effect of antiseptics on transepidermal water loss (TEWL). Status: unknown.
02
Drugs
HexidineTegaderm CHGpovidone-iodineSterilliumStellisept
03
Conditions
cutaneous reaction
Beyond the preview
Go deeper on 2006-005649-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005649-12.